Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Medicovestor Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is under the review of 1 distinct examiner, LI, RUIXIANG, who is also the busiest examiner with 1 pending action. The prosecution is localized in 1 distinct art unit, showing a concentrated technical focus for the company's current patent efforts.
With 1 pending office action and 1 distinct examiner, the company's current interaction with the patent office is limited to a single point of contact. LI, RUIXIANG is the sole examiner responsible for the pending matter. The alignment of 1 art unit and 1 examiner indicates a straightforward administrative structure for this specific patent application. This allows the applicant to focus entirely on the specific concerns of this one examiner, without the need to coordinate across multiple cases or different examining groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19055378 | METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN | LI, RUIXIANG | 25d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19055378 | METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN | LI, RUIXIANG | 1674 | §112 | Non-Final OA | 25d overdue | Pending | Feb 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial